Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: A systematic review and meta-analysis. The Breast Vol. 20(6), Dec 2011, p. 485-490.
Valachis, A., et al.
http://www.thebreastonline.com/article/S0960-9776(11)00135-4/abstract
Potentially eligible trials were located through PubMed and Cochrane Library searches and abstracts of major international conferences. The endpoints that we assessed were pathologic complete response (pCR) rate, breast-conserving surgery (BCS) rate and toxicity.
